By Elias Schisgall


Nvidia and Eli Lilly are partnering to launch a co-innovation lab to use Nvidia's artificial-intelligence and robotics expertise for drug discovery.

The companies said Monday they would invest up to $1 billion in talent, infrastructure, and computing power, including Nvidia's Vera Rubin chips, over the next five years. They said the new lab would expand the buildout of Lilly's Nvidia DGX SuperPOD and AI factory.

"We see this as a catalyst for the capabilities that will define the next era of drug discovery," Lilly Chief Information and Digital Officer Diogo Rau said. "We're moving toward a future where discovery is driven by rapid experimentation and increasingly customized models -- an approach that reflects our commitment to leading applied AI in drug discovery and investing deeply in new forms of data generation and model development."

Nvidia also said it was collaborating with Thermo Fisher to automate the company's research labs and data analysis.


Write to Elias Schisgall at elias.schisgall@wsj.com


(END) Dow Jones Newswires

01-12-26 1034ET